Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2002 June;54(3) > Minerva Ginecologica 2002 June;54(3):245-52

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2002 June;54(3):245-52

Copyright © 2002 EDIZIONI MINERVA MEDICA

language: Italian

Antiestrogen therapy in the treatment of breast neoplasms

Alba E., Ragonesi G., Colla F., Mazzoleni A., Farina C.


PDF  


During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion. Some studies compare or associate classic AE with the new SERMs and AI, both in adjuvant therapy and in treatment for advanced forms. Other trials assess the anti-osteoporotic activity of some SERMs which present concomitant inhibitory activity on the breast and endometrium.

top of page

Publication History

Cite this article as

Corresponding author e-mail